X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs BIOCON LTD - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA BIOCON LTD GSK PHARMA/
BIOCON LTD
 
P/E (TTM) x 62.9 81.4 77.4% View Chart
P/BV x 10.1 7.7 132.0% View Chart
Dividend Yield % 1.3 0.2 773.1%  

Financials

 GSK PHARMA   BIOCON LTD
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
BIOCON LTD
Mar-17
GSK PHARMA/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs3,8381,162 330.3%   
Low Rs2,637483 546.5%   
Sales per share (Unadj.) Rs354.2194.6 182.1%  
Earnings per share (Unadj.) Rs39.834.4 115.6%  
Cash flow per share (Unadj.) Rs42.948.3 88.8%  
Dividends per share (Unadj.) Rs30.001.00 3,000.0%  
Dividend yield (eoy) %0.90.1 761.9%  
Book value per share (Unadj.) Rs236.9241.9 98.0%  
Shares outstanding (eoy) m84.70200.00 42.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x9.14.2 216.3%   
Avg P/E ratio x81.423.9 340.7%  
P/CF ratio (eoy) x75.517.0 443.3%  
Price / Book Value ratio x13.73.4 402.0%  
Dividend payout %75.42.9 2,595.7%   
Avg Mkt Cap Rs m274,216164,440 166.8%   
No. of employees `0004.79.2 50.9%   
Total wages/salary Rs m4,8307,470 64.7%   
Avg. sales/employee Rs Th6,387.04,213.9 151.6%   
Avg. wages/employee Rs Th1,028.3809.0 127.1%   
Avg. net profit/employee Rs Th717.1745.2 96.2%   
INCOME DATA
Net Sales Rs m30,00038,911 77.1%  
Other income Rs m7281,571 46.4%   
Total revenues Rs m30,72840,482 75.9%   
Gross profit Rs m4,1909,795 42.8%  
Depreciation Rs m2632,772 9.5%   
Interest Rs m0260 0.0%   
Profit before tax Rs m4,6558,334 55.9%   
Minority Interest Rs m0163 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m4570-   
Tax Rs m1,7441,616 107.9%   
Profit after tax Rs m3,3686,881 48.9%  
Gross profit margin %14.025.2 55.5%  
Effective tax rate %37.519.4 193.2%   
Net profit margin %11.217.7 63.5%  
BALANCE SHEET DATA
Current assets Rs m16,74240,477 41.4%   
Current liabilities Rs m7,20216,783 42.9%   
Net working cap to sales %31.860.9 52.2%  
Current ratio x2.32.4 96.4%  
Inventory Days Days5260 86.9%  
Debtors Days Days2183 25.1%  
Net fixed assets Rs m8,63545,073 19.2%   
Share capital Rs m8471,000 84.7%   
"Free" reserves Rs m19,22247,377 40.6%   
Net worth Rs m20,06948,377 41.5%   
Long term debt Rs m1021,082 0.0%   
Total assets Rs m30,03893,942 32.0%  
Interest coverage xNM33.1-  
Debt to equity ratio x00.4 0.1%  
Sales to assets ratio x1.00.4 241.1%   
Return on assets %11.27.6 147.5%  
Return on equity %16.814.2 118.0%  
Return on capital %25.512.6 201.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m52812,988 4.1%   
Fx outflow Rs m7,1937,899 91.1%   
Net fx Rs m-6,6655,089 -131.0%   
CASH FLOW
From Operations Rs m2,3606,400 36.9%  
From Investments Rs m3,008-4,985 -60.3%  
From Financial Activity Rs m-5,108-1,775 287.8%  
Net Cashflow Rs m260-473 -55.0%  

Share Holding

Indian Promoters % 0.0 40.4 -  
Foreign collaborators % 50.7 20.6 246.1%  
Indian inst/Mut Fund % 10.2 8.4 121.4%  
FIIs % 23.8 10.7 222.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 19.9 77.4%  
Shareholders   102,036 109,995 92.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   DR. DATSONS LABS  STRIDES SHASUN LTD  J.B.CHEMICALS  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  

Compare GSK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Rising Dollar after Fed Minutes; F&O Expiry and Top Stocks in Action Today(Pre-Open)

Indian share markets ended largely flat on Thursday following the expiry of derivative contracts for February series. The S&P BSE Sensex ended down by 25 points.

Related Views on News

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Feb 22, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE GSK PHARMA WITH

MARKET STATS